Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3HP-2827 in unresectable/metastatic solid tumors with FGFR2 alterations
CTR20241063Phase 2Active
- Sponsor
- Sikang Ruiqi
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 3HP-2827 in Solid tumors harboring FGFR2 alterations, Nonhematologic neoplasms, Metastatic solid neoplasm, sponsored by Sikang Ruiqi. Started Jun 2024; status: active.
02
Drugs
3HP-2827
03
Conditions
Solid tumors harboring FGFR2 alterationsNonhematologic neoplasmsMetastatic solid neoplasm
Beyond the preview
Go deeper on CTR20241063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241063.